We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Moderna to Build mRNA Vaccine Portfolio Following COVID-19 Success
Moderna to Build mRNA Vaccine Portfolio Following COVID-19 Success
Moderna is following up on the success of its messenger RNA-based COVID-19 vaccine with plans to develop inoculations for numerous other infectious diseases, the company said Monday.